Back Hepatitis B Hepatitis B Topics HBV Disease Progression

EASL 2015: HBV Patients on Long-term Entecavir or Tenofovir Have Low Mortality, HCC Still a Risk

More than 95% of people with chronic hepatitis B were still alive after 5 years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread), and most deaths were due to non-liver-related causes, but hepatocellular carcinoma was still a major factor affecting mortality, researchers reported presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. 

alt

Read more:

EASL 2015: Prenylation Inhibitor Lonafarnib Lowers Hepatitis Delta Viral Load During Therapy

Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log in a Phase 2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Combining lonafarnib with pegylated interferon for 8 weeks led to significantly greater HDV RNA declines than lonafarnib alone, but boosting with ritonavir achieved an even greater effect with an all-oral regimen. HDV viral load rose again after stopping therapy, however, and researchers are now evaluating longer treatment durations.

alt

Read more:

EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment

Dramatic regional differences in survival rates for people with hepatocellular carcinoma (HCC) are largely attributable to varying national policies regarding screening and treatment, according to study findings presented at the 49thEASL International Liver Congress last week in London. Related research showed that percutaneous radiofrequency ablation is effective for treating single liver cancer tumors.

alt

Read more:

Everolimus Did Not Improve Survival for Advanced Liver Cancer Patients

The mTOR inhibitor everolimus (Afinator) failed to increase overall survival for people with advanced hepatocellular carccinoma (HCC) who were previously unsuccessfully treated with sorafenib, according to results from the EVOLVE-1 trial published in the July 2 edition of JAMA.

alt

Read more:

Increased Distance Reduces Likelihood of Liver Transplant

alt

Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.

Read more:

EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse

Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49thEASL International Liver Congress last week in London.

 

alt

Read more:

Can Coffee Help Prevent Liver Fibrosis?

There is good evidence that coffee has a beneficial effect in people at risk for liver fibrosis and there are plausible biological mechanisms to explain why, according to an editorial in the January 27 advance online edition of Hepatology. However, the amount needed to see such an effect may be too high for many people to tolerate, they cautioned.

alt

Read more: